NEW DIRECTIONS IN THE TREATMENT OF PEMPHIGUS VULGARIS? SAFETY AND EFFICACY OF RITUXIMAB AND DUPILUMAB – REVIEW OF LITERATURE
Abstract
Background. Recent years have demonstrated a considerable development of biological treatment of various autoimmune diseases. Lack of response and adverse effects of standard treatment have been pushing research to find new therapeutic agents with good efficacy and safety profile.
Aim. This study reviews the current knowledge about the potential use of rituximab and dupilumab, two biological drugs, in the treatment of pemphigus vulgaris (PV), a debilitating skin disease.
Material and methods. The article is based on research of clinical trials and case studies published on the PubMed and Cochrane databases using the following keywords: pemphigus vulgaris, rituximab, dupilumab.
Results. The existing trials show that rituximab offers faster achievement of complete remission when compared to standard prednisone or mycophenolate mofetil treatment. It also reduces the cumulative prednisone dose followed by alleviation of steroid-related adverse events. Its effect is even visible on the molecular level, being the depletion of T-helper cells that play a crucial role in activation of anti-desmoglein antibody producing B-memory cells. The use of dupilumab in PV has only been documented in a few case studies, which still show that most patients with refractory PV benefited from dupilumab treatment by finally achieving and maintaining remission.
Conclusions. Despite limited randomized studies and small patient groups, the results of the existing research suggest a promising role of biological agents in the future treatment of patients with pemphigus vulgaris.
References
Amber, K. T., & Hertl, M. (2015). An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol, 29(4), 777-782. https://doi.org/10.1111/jdv.12678
Bystryn, J. C., & Steinman, N. M. (1996). The adjuvant therapy of pemphigus. An update. Arch Dermatol, 132(2), 203-212.
Chen, D. M., Odueyungbo, A., Csinady, E., Gearhart, L., Lehane, P., Cheu, M., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., Paul, C., Richard, M. A., Bouaziz, J. D., Duvert-Lehembre, S., . . . Joly, P. (2020). Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol, 182(5), 1111-1119. https://doi.org/10.1111/bjd.18482
Chen, S., Zhan, S., Hua, C., Tang, Y., & Cheng, H. (2022). A Novel Combined Use of Dupilumab for Treatment of Aggressive Refractory Pemphigus Vulgaris Complicated With Pulmonary Tuberculosis: A Case Report and the RNA-seq Analysis. Front Immunol, 13, 825796. https://doi.org/10.3389/fimmu.2022.825796
Daneshpazhooh, M., Chams-Davatchi, C., Khamesipour, A., Mansoori, P., Taheri, A., Firooz, A., Mortazavi, H., Esmaili, N., & Dowlati, Y. (2007). Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. J Eur Acad Dermatol Venereol, 21(10), 1319-1324. https://doi.org/10.1111/j.1468-3083.2007.02254.x
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J., van de Winkel, J. G., Wilson, I. A., Koster, A. J., Taylor, R. P., Saphire, E. O., Burton, D. R., Schuurman, J., Gros, P., & Parren, P. W. (2014). Complement is activated by IgG hexamers assembled at the cell surface. Science, 343(6176), 1260-1263. https://doi.org/10.1126/science.1248943
Du, J., Wang, H., Zhong, C., Peng, B., Zhang, M., Li, B., Huo, S., Guo, Y., & Ding, J. (2007). Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem, 282(20), 15073-15080. https://doi.org/10.1074/jbc.M701654200
Fang, H., Li, Q., & Wang, G. (2020). The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun Rev, 19(11), 102661. https://doi.org/10.1016/j.autrev.2020.102661
Fishelson, Z., & Kirschfink, M. (2019). Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention. Front Immunol, 10, 752. https://doi.org/10.3389/fimmu.2019.00752
Hébert, V., Petit, M., Maho-Vaillant, M., Golinski, M. L., Riou, G., Derambure, C., Boyer, O., Joly, P., & Calbo, S. (2019). Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen. Front Immunol, 10, 1794. https://doi.org/10.3389/fimmu.2019.01794
Hébert, V., Vermeulin, T., Tanguy, L., Tedbirt, B., Mignard, C., Bénichou, J., & Joly, P. (2020). Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol, 183(1), 121-127. https://doi.org/10.1111/bjd.18563
Jiang, C., Adjei, S., Santiago, S., Lu, J., Duran, M., & Tyring, S. (2023). Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus. JAAD Case Rep, 42, 12-15. https://doi.org/10.1016/j.jdcr.2023.09.018
Joly, P., Horvath, B., Patsatsi, Α., Uzun, S., Bech, R., Beissert, S., Bergman, R., Bernard, P., Borradori, L., Caproni, M., Caux, F., Cianchini, G., Daneshpazhooh, M., De, D., Dmochowski, M., Drenovska, K., Ehrchen, J., Feliciani, C., Goebeler, M., . . . Schmidt, E. (2020). Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol, 34(9), 1900-1913. https://doi.org/10.1111/jdv.16752
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S., Caillot, F., Golinski, M. L., Labeille, B., Picard-Dahan, C., Paul, C., Richard, M. A., Bouaziz, J. D., Duvert-Lehembre, S., Bernard, P., Caux, F., Alexandre, M., Ingen-Housz-Oro, S., Vabres, P., . . . Musette, P. (2017). First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet, 389(10083), 2031-2040. https://doi.org/10.1016/s0140-6736(17)30070-3
Kamen, L., Myneni, S., Langsdorf, C., Kho, E., Ordonia, B., Thakurta, T., Zheng, K., Song, A., & Chung, S. (2019). A novel method for determining antibody-dependent cellular phagocytosis. J Immunol Methods, 468, 55-60. https://doi.org/10.1016/j.jim.2019.03.001
Lemieux, A., Maho-Vaillant, M., Golinski, M. L., Hébert, V., Boyer, O., Calbo, S., Candon, S., & Joly, P. (2022). Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus. JAMA Dermatol, 158(8), 893-899. https://doi.org/10.1001/jamadermatol.2022.2149
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013). A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol, 9(1), 30. https://doi.org/10.1186/1710-1492-9-30
Maho-Vaillant, M., Perals, C., Golinski, M. L., Hébert, V., Caillot, F., Mignard, C., Riou, G., Petit, M., Viguier, M., Hertl, M., Boyer, O., Calbo, S., Fazilleau, N., & Joly, P. (2021). Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus. J Invest Dermatol, 141(9), 2132-2140.e2131. https://doi.org/10.1016/j.jid.2021.01.031
McCann, M. R., Kosloski, M. P., Xu, C., Davis, J. D., & Kamal, M. A. (2024). Dupilumab: Mechanism of action, clinical, and translational science. Clin Transl Sci, 17(8), e13899. https://doi.org/10.1111/cts.13899
Mignard, C., Maho-Vaillant, M., Golinski, M. L., Balayé, P., Prost-Squarcioni, C., Houivet, E., Calbo, S. B., Labeille, B., Picard-Dahan, C., Konstantinou, M. P., Chaby, G., Richard, M. A., Bouaziz, J. D., Duvert-Lehembre, S., Delaporte, E., Bernard, P., Caux, F., Alexandre, M., Ingen-Housz-Oro, S., . . . Hébert, V. (2020). Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Dermatol, 156(5), 545-552. https://doi.org/10.1001/jamadermatol.2020.0290
Miše, J., Jukić, I. L., & Marinović, B. (2022). Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study. Front Immunol, 13, 884931. https://doi.org/10.3389/fimmu.2022.884931
Moore, A. Y., & Hurley, K. (2023). Dupilumab monotherapy suppresses recalcitrant pemphigus vulgaris. JAAD Case Rep, 31, 16-18. https://doi.org/10.1016/j.jdcr.2022.10.035
Mortensen, S. A., Sander, B., Jensen, R. K., Pedersen, J. S., Golas, M. M., Jensenius, J. C., Hansen, A. G., Thiel, S., & Andersen, G. R. (2017). Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. Proc Natl Acad Sci U S A, 114(5), 986-991. https://doi.org/10.1073/pnas.1616998114
Pierpont, T. M., Limper, C. B., & Richards, K. L. (2018). Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol, 8, 163. https://doi.org/10.3389/fonc.2018.00163
Porro, A. M., Seque, C. A., Ferreira, M. C. C., & Enokihara, M. (2019). Pemphigus vulgaris. An Bras Dermatol, 94(3), 264-278. https://doi.org/10.1590/abd1806-4841.20199011
Robinson, A. J., Vu, M., Unglik, G. A., Varigos, G. A., & Scardamaglia, L. (2018). Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients. Australas J Dermatol, 59(1), e47-e52. https://doi.org/10.1111/ajd.12571
Shimanovich, I., Baumann, T., Schmidt, E., Zillikens, D., & Hammers, C. M. (2020). Long-term outcomes of rituximab therapy in pemphigus. J Eur Acad Dermatol Venereol, 34(12), 2884-2889. https://doi.org/10.1111/jdv.16561
Singh, N., Handa, S., Mahajan, R., Sachdeva, N., & De, D. (2022). Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clin Exp Dermatol, 47(8), 1508-1516. https://doi.org/10.1111/ced.15213
Taylor, R., Lindorfer, M. (2007). Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis. Nat Rev Rheumatol, 3, 86-95.
Werth, V. P., Joly, P., Mimouni, D., Maverakis, E., Caux, F., Lehane, P., Gearhart, L., Kapre, A., Pordeli, P., & Chen, D. M. (2021). Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris. N Engl J Med, 384(24), 2295-2305. https://doi.org/10.1056/NEJMoa2028564
Zhong, S., Qiu, Y. F., Han, B. B., Zhao, J. Y., Zhu, X. J., & Chen, X. X. (2011). [Detection of serum desmoglein antibody level using enzyme-linked immunosorbent assay (ELISA) for monitoring disease activity in patients with pemphigus vulgaris]. Beijing Da Xue Xue Bao Yi Xue Ban, 43(3), 414-415.
Views:
20
Downloads:
10
Copyright (c) 2025 Alicja Bury, Karol Bartecki, Natalia Kraciuk, Katarzyna Krupa, Małgorzata Piekarska-Kasperska, Anna Daniel, Julia Błoniecka, Kacper Jankowski, Jan Kamiński
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
